Clinical trials play a crucial role in the development of new medicines and for the progress of evidence-based medicine. Teva sponsors well-designed, carefully conducted clinical trials to determine the safety and effectiveness of new drugs and treatments which translate into improved clinical care. 

Information on ongoing clinical trials that are sponsored by Teva is available to the public free of charge at www.clinicaltrials.gov (type Teva into the search box to see a list of Teva trials posted on clinicaltrials.gov). The registry contains basic information about each trial for you and/or your healthcare practitioners. This information is not intended to be a substitute for the informed medical advice or medical treatment of a healthcare professional who can determine if a specific medicine is appropriate for a particular patient. If you have questions regarding any information contained in this site, you should consult advice from a qualified healthcare professional.

Expanded Access Programs

Teva supports requests for expanded access programs that meet the criteria outlined in our Policy on Expanded Access programs. Expanded access, also called “compassionate use", provides a pathway for patients to gain access to investigational drugs, biologics and medical devices for serious diseases or conditions.

To submit a request for an expanded access program, please complete this form and email it to ExpandedAccess@tevapharm.com. Teva will respond within 1 business day to confirm receipt of the request and to outline next steps.

• If you are requesting expanded access use for former TV48125-CNS-30051 (HALO) OR TV48125-CNS 30068 (FOCUS) patients, you must complete and sign this HALO/FOCUS checklist in addition to the expanded access request form. Both documents should be emailed to ExpandedAccess@tevapharm.com.

This website and policy will be updated with a hyperlink or other reference to the expanded access record on clinicaltrials.gov after such record becomes active.